Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292577 · ClinicalTrials.gov registry record · Phase 1
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01292577 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 33 participants.
The verdict
NCT01292577, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy \[CET\]) and an affect regulation (Personal Therapy \[PT\]) intervention for 50 individuals with schizophrenia that misuse cannabis. Participants will be randomized to CET/PT plus treatment as usual (TAU) or TAU alone and treated for 18 months.
Interventions
- BEHAVIORAL Treatment as Usual
- BEHAVIORAL CET/PT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01292577
The ClinicalTrials.gov registry entry for NCT01292577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment as Usual is the first listed.
NCT01292577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01292577 about?
NCT01292577 is a clinical study titled "Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia". This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy \[CET\]) and an affect regulation (Personal Therapy \[PT\]) intervention for 50 individuals with schizophrenia that misuse cannabis. Participants will be randomized to CET/PT plus treatment as usual (TAU) or T...
What is the current status of trial NCT01292577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2010-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01292577?
The interventions under investigation include: Treatment as Usual (BEHAVIORAL), CET/PT (BEHAVIORAL).
Who is sponsoring clinical trial NCT01292577?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.